Antitumor necrosis factor (TNF-a) antibodies in the treatment of renal cell cancer

Cancer Investigation

Volumn 25, Issue 7, 2007, Pages 589-593

  Maisey, Nick ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Infliximab; Renal cell carcinoma; Tumor necrosis factor

Indexed keywords

ALPHA INTERFERON; CYTOKINE; FLUOROURACIL; INFLIXIMAB; INTERLEUKIN 2; MATRIX METALLOPROTEINASE; SORAFENIB; SUNITINIB; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; CANCER MODEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CROHN DISEASE; DRUG ACTIVITY; DRUG HYPERSENSITIVITY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG STABILITY; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SKIN CANCER; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; KIDNEY NEOPLASMS; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 36248994099     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701359700     Document Type: Article

References (39)

1. Godley, P.A.; Taylor, M. Renal cell carcinoma. Curr. Opin. Oncol. 2001, 13 (3), 199-203.
2. Chow, W.H.; Devesa, S.S.; Warren, J.L.; Fraumeni, J.F., Jr. Rising incidence of renal cell cancer in the United States. JAMA 1999, 281 (17), 1628-1631.
3. Lam, J.; Breda, A.; Belldegrun, A.S.; Figlin, R.A. Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma. J. Clin. Oncol. 2006, 24 (35), 5565-5575.
4. Campbell, S.C.; Flanigan, R.C.; Clark, J.I. Nephrectomy in metastatic renal cell carcinoma. Curr. Treat. Options Oncol. 2003, 4 (5), 363-372.
5. Amato, R.J. Chemotherapy for renal cell carcinoma. Semin. Oncol. 2000, 27 (2), 177-186.
6. Milowsky, M.I.; Nanus, D.M. Chemotherapeutic strategies for renal cell carcinoma. Urol. Clin. North. Am. 2003 30 (3), 601-609.
7. Amato, R.J. Thalidomide therapy for renal cell carcinoma. Crit. Rev. Oncol. Hematol. 2003, 27 (Suppl. 46), S59-S65.
8. Pyrhonen, S.; Salminen, E.; Ruutu, M.; Lehtonen, T.; Nurmi, M.; et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J. Clin. Oncol. 1999, 17 (9), 2859-2867.
9. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999, 353 (9146), 14-17.
10. Minasian, L.M.; Motzer, R.J.; Gluck, L.; Mazumdar, M.; Vlamis, V.; Krown, S.E. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J. Clin. Oncol. 1993, 11 (7), 1368-1375.
11. B. Escudier, B.; Szczylik, C.; Eisen, T.; Stadler, W. M.; Schwartz, B.; Shan, M.; Bukowski, R.M. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. 2005, (Abstr. 4510).
12. Motzer, R.J.; Rini, B.I.; Michaelson, M.D.; Redman, B.G.; Hudes, G.R.; Wilding, G.; Bukowski, R.M.; George D.J.; Kim, S.T.; Baum, C.M. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. 2005, (Abstr. 4508).
13. Motzer, R.J.; Michaelson, M.D.; Redman, B.G.; et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2006, 24 (1), 16-24
14. Balkwill, F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 2002, 13 (2), 135-141.
15. Locksley, R.M.; Killeen, N.; Lenardo, M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001, 104 (4), 487-501.
16. Szlosarek, P.W.; Balkwill, F.R. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol. 2003, 4 (9), 565-573.
17. Mizutani, Y.; Bonavida, B.; Nio, Y.; Yoshida, O. Overcoming TNFalpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNF-alpha mRNA downregulation in tumor cell sensitization. J. Urol. 1994, 151 (6), 1697-1702.
18. Tselepis, C.; Perry, I.; Dawson, C.; et al. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene 2002, 21 (39), 6071-81.
19. Wu, S.; Boyer, C.M.; Whitaker, R.S.; et al. Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res. 1993, 53 (8), 1939-1944.
20. Gaiotti, D.; Chung, J.; Iglesias, M.; et al. Tumor necrosis factor-alpha promotes human papillomavirus (HPV) E6/E7 RNA expression and cyclin-dependent kinase activity in HPV-immortalized keratinocytes by a ras-dependent pathway. Mol. Carcinog. 2000, 27 (2), 97-109.
21. Moore, R.J.; Owens, D.M.; Stamp, G.; et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat. Med. 1999, 5 (7), 828-831.
22. Eisen, T.; Boshoff, C.; Mak, I.; et al. Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br. J. Cancer 2000, 82 (4), 812-817.
23. Stebbing, J.; Benson, C.; Eisen, T.; et al. The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br. J. Cancer 2001, 85 (7), 953-958.
24. Daliani, D.D.; Papandreou, C.N.; Thall, P.F.; et al. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer 2002, 95 (4), 758-765.
25. Escudier, B.; Lassau, N.; Couanet, D.; et al. Phase II trial of thalidomide in renal-cell carcinoma. Ann. Oncol. 2002, 13 (7), 1029-1035.
26. Motzer, R.J.; Berg, W.; Ginsberg, M.; et al. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J. Clin. Oncol. 2002, 20 (1), 302-306.
27. Minor, D.R.; Monroe, D.; Damico, L.A.; Meng, G.; Suryadevara, U.; Elias, L. A phase II study of thalidomide in advanced metastatic renal cell carcinoma. Invest. New Drugs 2002, 20 (4), 389-393.
28. Novik, Y.; Dutcher, J.P.; Larkin, M. Phase II study of thalidomide (T) in advanced refractory metastatic renal cell carcinoma (MRCC): A single institution experience. Proc. Am. Soc. Clin. Oncol. 2001, 265a (Abstr. 1057).
29. Li, Z.; Amato, R.; Papandreou, C.N. Phase II study of thalidomide for patients with metastatic renal cell cancer (MRCC) progressing after interleukin-2 (IL-2)-based therapy (Rx). Proc. Am. Soc. Clin. Oncol. 2001, 180a (Abstr. 717).
30. Ching, L.M.; Xu, Z.F.; Gummer, B.H.; Palmer, B.D.; Joseph, W.R.; Baguley, B.C. Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br. J. Cancer 1995, 72 (2), 339-343.
31. Knight, D.M.; Trinh, H.; Le, J.; et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol. 1993, 30 (16), 1443-1453.
32. Scallon, B.J.; Moore, M.A.; Trinh, H.; Knight, D.M.; Ghrayeb, J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995, 7 (3), 251-259.
33. Maini, R.; St. Clair, E.W.; Breedveld, F.; et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354 (9194), 1932-1939.
34. Maisey, N.; Hall, K.; Lee, C.; Timotheadou, E.; Ahern, R.; Eisen, T.; Gore, M. Infliximab: A Phase II Trial Of The Tumour Necrosis Factor (TNF) Monoclonal Antibody In Patients With Advanced Renal Cell Cancer (RCC). Proc. Am. Soc. Clin. Oncol. 2004 (Abstr. 4514).
35. Weidmann, E.; Bergmann, L.; Stock, J.; Kirsten, R.; Mitrou, P.S. Rapid cytokine release in cancer patients treated with interleukin-2. J. Immunother. 1992, 12 (2), 123-131.
36. Lopez Hanninen, E.; Kirchner, H.; Atzpodien, J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J. Urol. 1996, 155 (1), 19-25.
37. Balkwill, F. Cancer and the chemokine network. Nat. Rev. Cancer. 2004, 4 (7), 540-550.
38. Mantovani, A.; Bottazzi, B.; Colotta, F.; Sozzani, S.; Ruco, L. The origin and function of tumor-associated macrophages. Immunol. Today 1992, 13 (7), 265-270.
39. Conti, I.; Rollins, B.J. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin. Cancer Biol. 2004, 14 (3), 149-154.